ACST
Income statement / Annual
Last year (2023), Acasti Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Acasti Pharma Inc.'s net income was -$12.85 M.
See Acasti Pharma Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
02/29/2016 |
02/28/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$196,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$27,788.00
|
$216,289.00
|
| Cost of Revenue |
$11,000.00 |
$52.16 M |
$15.59 M |
$76,000.00 |
$2.32 M |
$2.33 M |
$0.00 |
$0.00 |
$60,082.00 |
$187,896.00 |
| Gross Profit |
-$11,000.00 |
-$52.16 M |
-$15.59 M |
$120,000.00 |
-$2.32 M |
-$2.33 M |
$0.00 |
$0.00 |
-$32,294.00 |
$28,393.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0.61 |
0 |
0 |
0 |
0 |
-1.16 |
0.13 |
| Research and Development
Expenses |
$4.63 M
|
$9.97 M
|
$5.56 M
|
$4.17 M
|
$15.97 M
|
$28.73 M
|
$12.13 M
|
$0.00
|
$5.45 M
|
$5.21 M
|
| General & Administrative
Expenses |
$6.43 M
|
$8.08 M
|
$9.26 M
|
$5.51 M
|
$5.80 M
|
$4.24 M
|
$3.12 M
|
$0.00
|
$1.61 M
|
$4.72 M
|
| Selling & Marketing
Expenses |
-$252,000.00
|
$136,000.00
|
$518,000.00
|
$1.14 M
|
$2.67 M
|
$660.15
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.67 M
|
$8.21 M
|
$9.78 M
|
$6.66 M
|
$8.46 M
|
$4.24 M
|
$3.12 M
|
$0.00
|
$1.61 M
|
$4.72 M
|
| Other Expenses |
$0.00 |
$63,000.00 |
$0.00 |
$8,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$11.30 M |
$18.25 M |
$15.34 M |
$10.84 M |
$24.44 M |
$32.97 M |
$15.25 M |
$0.00 |
$7.06 M |
$9.93 M |
| Cost And Expenses |
$11.31 M |
$18.25 M |
$15.34 M |
$10.91 M |
$24.44 M |
$32.97 M |
$15.25 M |
$0.00 |
$7.12 M |
$10.12 M |
| Interest Income |
$0.00 |
$246,000.00 |
$77,000.00 |
$107,000.00 |
$336,000.00 |
$355,751.00 |
$55,753.00 |
$0.00 |
$54,235.00 |
$69,542.00 |
| Interest Expense |
$911,000.00 |
$67.69 M |
$224,000.00 |
$264,000.00 |
$247,000.00 |
$273,367.00 |
$283,411.00 |
$0.00 |
$1,668.50 |
$3,244.96 |
| Depreciation &
Amortization |
$11,000.00
|
$124,000.00
|
$1.16 M
|
$924,000.00
|
$2.32 M
|
$2.73 M
|
$1.24 M
|
$22,816.00
|
$1.77 M
|
$1.87 M
|
| EBITDA |
-$11.30 M
|
$15.85 M
|
-$19.99 M
|
-$9.95 M
|
-$21.83 M
|
-$30.99 M
|
-$14.01 M
|
$0.00
|
-$5.27 M
|
-$7.97 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-50.76 |
0 |
0 |
0 |
0 |
-189.7 |
-36.85 |
| Operating Income Ratio
|
0
|
0
|
0
|
-54.67
|
0
|
0
|
0
|
0
|
-255.24
|
-45.8
|
| Total Other
Income/Expenses Net |
-$3.32 M
|
-$67.69 M
|
$5.12 M
|
-$8.96 M
|
-$1.08 M
|
-$4.91 M
|
-$1.40 M
|
$0.00
|
$2.38 M
|
$8.52 M
|
| Income Before Tax |
-$14.63 M |
-$51.97 M |
-$10.47 M |
-$19.68 M |
-$25.51 M |
-$38.62 M |
-$16.65 M |
$0.00 |
-$4.66 M |
-$1.32 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
0
|
-167.75
|
-6.11
|
| Income Tax Expense |
-$1.78 M |
-$9.54 M |
-$648,000.00 |
-$127,000.00 |
$247,000.00 |
$5.24 M |
$291,154.00 |
$0.00 |
-$2.38 M |
-$8.52 M |
| Net Income |
-$12.85 M |
-$42.43 M |
-$9.82 M |
-$19.68 M |
-$25.76 M |
-$43.86 M |
-$16.94 M |
$0.00 |
-$4.66 M |
-$1.32 M |
| Net Income Ratio |
0 |
0 |
0 |
-100.4 |
0 |
0 |
0 |
0 |
-167.75 |
-6.11 |
| EPS |
-1.35 |
-5.71 |
-1.6 |
-7.96 |
-14.62 |
-6.46 |
-7.75 |
0 |
-20.99 |
-5.98 |
| EPS Diluted |
-1.35 |
-5.71 |
-1.6 |
-7.96 |
-14.62 |
-6.46 |
-7.75 |
0 |
-20.99 |
-5.98 |
| Weighted Average Shares
Out |
$9.53 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$6.79 M
|
$2.19 M
|
$2.19 M
|
$222,082.00
|
$221,202.00
|
| Weighted Average Shares
Out Diluted |
$9.53 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$6.79 M
|
$2.19 M
|
$2.19 M
|
$222,082.00
|
$221,202.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
